InfuSystem Holdings, Inc. $INFU Shares Sold by Goldman Sachs Group Inc.

Goldman Sachs Group Inc. lessened its stake in shares of InfuSystem Holdings, Inc. (NYSE:INFU) by 9.8% during the first quarter, Holdings Channel.com reports. The institutional investor owned 81,634 shares of the company’s stock after selling 8,895 shares during the period. Goldman Sachs Group Inc.’s holdings in InfuSystem were worth $439,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the stock. Minerva Advisors LLC grew its holdings in InfuSystem by 7.5% during the 1st quarter. Minerva Advisors LLC now owns 910,677 shares of the company’s stock valued at $4,899,000 after buying an additional 63,826 shares during the last quarter. Russell Investments Group Ltd. grew its holdings in InfuSystem by 13.1% during the 1st quarter. Russell Investments Group Ltd. now owns 437,891 shares of the company’s stock valued at $2,356,000 after buying an additional 50,877 shares during the last quarter. Cove Street Capital LLC grew its holdings in InfuSystem by 8.7% during the 1st quarter. Cove Street Capital LLC now owns 210,301 shares of the company’s stock valued at $1,131,000 after buying an additional 16,851 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in InfuSystem by 4.7% during the 1st quarter. Bank of New York Mellon Corp now owns 95,471 shares of the company’s stock valued at $514,000 after buying an additional 4,252 shares during the last quarter. Finally, Nuveen LLC purchased a new position in shares of InfuSystem during the 1st quarter worth $465,000. Institutional investors and hedge funds own 71.13% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have weighed in on INFU. Roth Capital began coverage on InfuSystem in a research note on Tuesday, July 22nd. They set a “buy” rating and a $12.00 price target on the stock. Lake Street Capital began coverage on InfuSystem in a research note on Monday, September 22nd. They set a “buy” rating and a $15.00 price target on the stock. Three investment analysts have rated the stock with a Strong Buy rating and one has issued a Buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Strong Buy” and an average price target of $13.50.

Insider Activity at InfuSystem

In other InfuSystem news, Director Scott Shuda sold 5,752 shares of the business’s stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $9.67, for a total transaction of $55,621.84. Following the transaction, the director owned 94,000 shares in the company, valued at $908,980. The trade was a 5.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 11.40% of the stock is currently owned by corporate insiders.

InfuSystem Price Performance

Shares of InfuSystem stock opened at $10.34 on Friday. InfuSystem Holdings, Inc. has a twelve month low of $4.61 and a twelve month high of $11.04. The stock has a market capitalization of $211.20 million, a P/E ratio of 172.36 and a beta of 1.82. The company has a current ratio of 1.98, a quick ratio of 1.59 and a debt-to-equity ratio of 0.50. The business’s fifty day moving average price is $8.89 and its 200 day moving average price is $6.74.

InfuSystem Company Profile

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.